<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01360346</url>
  </required_header>
  <id_info>
    <org_study_id>SedaENvsIV</org_study_id>
    <nct_id>NCT01360346</nct_id>
  </id_info>
  <brief_title>Enteral Versus Intravenous Sedation in Critically Ill High-risk ICU Patients</brief_title>
  <official_title>Multicentric, Single Blind, Randomized Controlled Trial on Enteral Sedation Versus Intravenous Sedation in Critically Ill High-risk ICU Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Milan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ospedale San Paolo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ospedale Maggiore Policlinico Mangiagalli e Regina Elena</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Ospedaliera San Gerardo di Monza</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Ospedaliera Niguarda Cà Granda</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Ospedaliera Fatebenefratelli e Oftalmico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>IRCCS Policlinico S. Matteo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>San Luigi Gonzaga Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ospedale S. Giovanni Bosco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ospedale Cardinal Massaia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Ospedaliera, Ospedale Civile di Legnano</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nuovo Ospedale Civile S.Agostino Estense</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Milan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent studies suggest the employment of 'conscious' sedation (1) for critically high - risk
      patients (2), showing more efficacy then deep sedation (3). The investigators want to compare
      intravenous injection versus enteral sedative drugs administration, purposing to maintain a
      'conscious' sedation level compatibly with the needed cares, invasive procedures, and medical
      and nursing surveillance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recent studies suggest the employment of 'conscious' sedation for critically high - risk
      patients (2), showing more efficacy then deep sedation (3). From this point of view it's
      important to consider both the choice of sedative drugs and the way to administer them to
      maintain the constant 'conscious' sedation level that the investigators wanted.

      This research compares two different procedures for sedation therapy: through a randomized
      and blind controlled trial the interventional group will collect patients receiving sedatives
      from enteral way (4, 5, 6). In the control arm, sedation administration forecasts intravenous
      injection (7), recognised like the best practice in the most of intensive care units of the
      world.

      To consider two different clinical approach for administration the investigators have to use
      different molecules: in the control arm propofol and midazolam will be continuously
      administered through intravenous injection with daily suspension (7); in the intervention arm
      the investigators will administer melatonin like a physiological hypnotic inductor (6), the
      continuous 'conscious' sedation will be maintained through hydroxyzine and eventually
      lorazepam (4), and all the active principles will be given by enteral administration.

      The goal of the study is to compare intravenous injection versus enteral sedative drugs
      administration, analysing their efficacy and the feasibility to maintain constant the
      appropriate sedation level (RASS measured = RASS wished ±1) (8) in high - risk patients
      admitted in Intensive Care Unit (2), purposing to conserve a 'conscious' sedation level
      compatibly with the needed cares, invasive procedures, and medical and nursing surveillance.

      MATERIALS AND METHODS Prospective, randomized and controlled multicentric, single blind
      trial. Participant ICU centres: San Paolo MI (Iapichino), Policlinico MI (Gattinoni) ,
      Fatebenefratelli MI (Cigada), Niguarda MI (De Gasperi), Desio (Ronzoni), Legnano
      (Radrizzani), Monza (Pesenti), Belluno (Mazzon), Lugano (Malacrida), Modena (Rambaldi),
      Torino (Livigni), Asti (Cardellino).

      PROCEDURE Bare minimum sedation drug titration will be done to maintain and to achieve
      prematurely a 'conscious' sedation level (RASS=0). During every shift it will be discussed
      the appropriate sedation therapy: if physicians choose a deep sedation goal (RASS &lt;-3) this
      decision has to be explained and registered; then enteral sedation has to be maximized in
      randomized enteral patients group. If necessary intravenous sedation has to be added , and
      this procedure dose not represent a violation of research protocol.

      If there is pain (VNR&gt;3 or BPS&gt;6) it will be administrated analgesic therapy according to
      hospital guidelines bare minimum duration. The treatment of procedural pain will be applied
      both groups trough Fentanest/Morphine + propofol/midazolam bolus intravenous, this procedure
      dose not represent a violation of research protocol.

      If acute cerebral malfunction appears (CAM-ICU positive), it will be administrated
      haloperidol (1mg per os, max 10 mg/die) or other antipsychotic therapy according to hospital
      guidelines.

      Enteral artificial nutrition with prokinetics will be started as soon as possible both group,
      while parenteral nutrition will be administered only if strictly necessary. If gastric
      stagnation &gt; 200 ml/4 hours exceeds 2 days duration, it could be positioned nasogastric tube
      or digiunostomy.

      All patients will be sit in a semiortopnoic position (bed back rest inclination between 30
      and 45°).

      STUDY POWER AND STATISTICAL ANALYSIS The investigators suppose to obtain a difference of 15%
      per cent between two arms for patients' sedation adequacy benefit (RASS = desired RASS + 1).
      Knowing that the enteral approach reached 83% adequacy from a observational monocentric
      research (5), it should be necessary to enrol 141 patients for each arm (power 80%). In
      consideration of the missing data, the investigators expect to enroll 300 patients. An &quot;ad
      interim&quot; statistical analysis is planned after the enrollment of 70 patients in each group.

      To provide a statistical analysis as &quot;Intention To Treat&quot; for possible arms change risk.

      It's planned to obtain a selective analysis involving each hospital included in the study.

      It's planned to obtain a selective analysis about septic patients (greater delirium
      prevalence) (9).

      It's planned to obtain a selective analysis divided for age (greater delirium prevalence if
      age &gt;70) (10).

      The randomization will be achieved trough out a particular Internet Website with a specific
      program expressly built. It will be used minimization technique to maintain groups balanced
      in the patients' sample of each centre.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">October 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of efficacy, measured by observed RASS = desired RASS ± 1.</measure>
    <time_frame>One year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sedation protocol effectiveness: percentage of &quot;protocol violation days&quot; on the total of ICU days.</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delirium and coma free days (respectively negative CAM-ICU and RASS &gt; - 3 in all daily observations until 28° ICU day) (11)</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilation free days (12)</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nursing evaluation of sedation adequacy (communication skills, cooperation, environment tolerance) (13)</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall ICU and hospital mortality, absolute mortality after 1 year from ICU discharge.</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sedative drugs costs.</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Indirect inefficacy markers</measure>
    <time_frame>One year</time_frame>
    <description>Prevalence of 'dangerous episodes': self - extubation, removal of other invasive clinical instruments;
Length of ICU and hospital stay
Use of anti-psychotic drugs (indirect delirium marker)
Other indicators of sedation failure: use of restraining therapies, antagonist administrations (fluamzenil - naloxone).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Critical Illness</condition>
  <condition>Mechanical Ventilation Complication</condition>
  <arm_group>
    <arm_group_label>Enteral Sedation (EN)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Melatonin, Hydroxyzine, and Lorazepam. At every work shift, it will be checked the possibility to decrease the Lorazepam and then the Hydroxyzine dosage to quickly obtain and continuously maintain a RASS level = 0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous Sedation (IV)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous propofol or midazolam administration at the ICU admission to discharge at the compatible lowest level with harsh ICU environment. At every shift nurses are requested to give intravenous lowest dosage to obtain RASS=0</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Enteral Sedation (EN)</intervention_name>
    <description>Intravenous propofol or midazolam administration at the ICU admission and stopped within 48h. Melatonin by enteral route (3mg x 2/die) from admission to discharge. Hydroxyzine by enteral route from ICU admission (600mg/die), decreased and stopped as soon as possible. Lorazepam supplementation (maximum 16mg/die) if hydroxyzine is inadequate.</description>
    <arm_group_label>Enteral Sedation (EN)</arm_group_label>
    <other_name>ENTERAL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Control group: Intravenous Sedation (IV)</intervention_name>
    <description>Propofol or midazolam from ICU admission to discharge at the compatible lowest level with harsh ICU environment.</description>
    <arm_group_label>Intravenous Sedation (IV)</arm_group_label>
    <other_name>INTRAVENOUS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  High Risk Patients (Ventilation days assessment &gt;3, SAPS II &gt;32).

          -  Until 24 h after ICU admission

          -  Age &gt; 18 years

        Exclusion Criteria:

          -  Neurosurgical patients

          -  Allergy to medications used in the study

          -  CNS diseases (epilepsy, ictus, dementia, anoxic coma…)

          -  Liver encephalopathy (Child C)

          -  Previous psychiatric or cognitive pathology

          -  Absolute contraindications to use enteral route (acceptable NGT, digiunostomy,
             ileostomy)

          -  Pregnant patients or in breast-feeding

          -  DNR patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Iapichino Gaetano, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Milan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Giovanni Mistraletti, MD</last_name>
    <phone>+39.339.8245014</phone>
    <email>giovanni.mistraletti@unimi.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>AO San Paolo - Polo Universitario</name>
      <address>
        <city>Milano</city>
        <zip>20142</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni Mistraletti, MD</last_name>
      <phone>+39.339.8245014</phone>
      <email>giovanni.mistraletti@unimi.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Strøm T, Martinussen T, Toft P. A protocol of no sedation for critically ill patients receiving mechanical ventilation: a randomised trial. Lancet. 2010 Feb 6;375(9713):475-80. doi: 10.1016/S0140-6736(09)62072-9. Epub 2010 Jan 29.</citation>
    <PMID>20116842</PMID>
  </reference>
  <reference>
    <citation>Iapichino G, Mistraletti G, Corbella D, Bassi G, Borotto E, Miranda DR, Morabito A. Scoring system for the selection of high-risk patients in the intensive care unit. Crit Care Med. 2006 Apr;34(4):1039-43.</citation>
    <PMID>16484895</PMID>
  </reference>
  <reference>
    <citation>Payen JF, Chanques G, Mantz J, Hercule C, Auriant I, Leguillou JL, Binhas M, Genty C, Rolland C, Bosson JL. Current practices in sedation and analgesia for mechanically ventilated critically ill patients: a prospective multicenter patient-based study. Anesthesiology. 2007 Apr;106(4):687-95; quiz 891-2.</citation>
    <PMID>17413906</PMID>
  </reference>
  <reference>
    <citation>Cigada M, Pezzi A, Di Mauro P, Marzorati S, Noto A, Valdambrini F, Zaniboni M, Astori M, Iapichino G. Sedation in the critically ill ventilated patient: possible role of enteral drugs. Intensive Care Med. 2005 Mar;31(3):482-6. Epub 2005 Feb 16.</citation>
    <PMID>15714324</PMID>
  </reference>
  <reference>
    <citation>Cigada M, Corbella D, Mistraletti G, Forster CR, Tommasino C, Morabito A, Iapichino G. Conscious sedation in the critically ill ventilated patient. J Crit Care. 2008 Sep;23(3):349-53. doi: 10.1016/j.jcrc.2007.04.003. Epub 2007 Jul 5.</citation>
    <PMID>18725039</PMID>
  </reference>
  <reference>
    <citation>Mistraletti G, Sabbatini G, Taverna M, Figini MA, Umbrello M, Magni P, Ruscica M, Dozio E, Esposti R, DeMartini G, Fraschini F, Rezzani R, Reiter RJ, Iapichino G. Pharmacokinetics of orally administered melatonin in critically ill patients. J Pineal Res. 2010 Mar;48(2):142-7. doi: 10.1111/j.1600-079X.2009.00737.x. Epub 2010 Jan 8.</citation>
    <PMID>20070489</PMID>
  </reference>
  <reference>
    <citation>Girard TD, Kress JP, Fuchs BD, Thomason JW, Schweickert WD, Pun BT, Taichman DB, Dunn JG, Pohlman AS, Kinniry PA, Jackson JC, Canonico AE, Light RW, Shintani AK, Thompson JL, Gordon SM, Hall JB, Dittus RS, Bernard GR, Ely EW. Efficacy and safety of a paired sedation and ventilator weaning protocol for mechanically ventilated patients in intensive care (Awakening and Breathing Controlled trial): a randomised controlled trial. Lancet. 2008 Jan 12;371(9607):126-34. doi: 10.1016/S0140-6736(08)60105-1.</citation>
    <PMID>18191684</PMID>
  </reference>
  <reference>
    <citation>Sessler CN, Gosnell MS, Grap MJ, Brophy GM, O'Neal PV, Keane KA, Tesoro EP, Elswick RK. The Richmond Agitation-Sedation Scale: validity and reliability in adult intensive care unit patients. Am J Respir Crit Care Med. 2002 Nov 15;166(10):1338-44.</citation>
    <PMID>12421743</PMID>
  </reference>
  <reference>
    <citation>Pandharipande PP, Sanders RD, Girard TD, McGrane S, Thompson JL, Shintani AK, Herr DL, Maze M, Ely EW; MENDS investigators. Effect of dexmedetomidine versus lorazepam on outcome in patients with sepsis: an a priori-designed analysis of the MENDS randomized controlled trial. Crit Care. 2010;14(2):R38. doi: 10.1186/cc8916. Epub 2010 Mar 16. Erratum in: Crit Care. 2011;15(1):402.</citation>
    <PMID>20233428</PMID>
  </reference>
  <reference>
    <citation>Inouye SK. Delirium in older persons. N Engl J Med. 2006 Mar 16;354(11):1157-65. Review. Erratum in: N Engl J Med. 2006 Apr 13;354(15):1655.</citation>
    <PMID>16540616</PMID>
  </reference>
  <reference>
    <citation>Pandharipande PP, Pun BT, Herr DL, Maze M, Girard TD, Miller RR, Shintani AK, Thompson JL, Jackson JC, Deppen SA, Stiles RA, Dittus RS, Bernard GR, Ely EW. Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients: the MENDS randomized controlled trial. JAMA. 2007 Dec 12;298(22):2644-53.</citation>
    <PMID>18073360</PMID>
  </reference>
  <reference>
    <citation>Schoenfeld DA, Bernard GR; ARDS Network. Statistical evaluation of ventilator-free days as an efficacy measure in clinical trials of treatments for acute respiratory distress syndrome. Crit Care Med. 2002 Aug;30(8):1772-7.</citation>
    <PMID>12163791</PMID>
  </reference>
  <reference>
    <citation>Riker RR, Shehabi Y, Bokesch PM, Ceraso D, Wisemandle W, Koura F, Whitten P, Margolis BD, Byrne DW, Ely EW, Rocha MG; SEDCOM (Safety and Efficacy of Dexmedetomidine Compared With Midazolam) Study Group. Dexmedetomidine vs midazolam for sedation of critically ill patients: a randomized trial. JAMA. 2009 Feb 4;301(5):489-99. doi: 10.1001/jama.2009.56. Epub 2009 Feb 2.</citation>
    <PMID>19188334</PMID>
  </reference>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2011</study_first_submitted>
  <study_first_submitted_qc>May 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2011</study_first_posted>
  <last_update_submitted>April 23, 2012</last_update_submitted>
  <last_update_submitted_qc>April 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Milan</investigator_affiliation>
    <investigator_full_name>Giovanni Mistraletti</investigator_full_name>
    <investigator_title>University Researcher</investigator_title>
  </responsible_party>
  <keyword>Enteral Sedation</keyword>
  <keyword>Intravenous Sedation</keyword>
  <keyword>Critically ill ICU patient</keyword>
  <keyword>Conscious Sedation</keyword>
  <keyword>Deep Sedation</keyword>
  <keyword>RASS</keyword>
  <keyword>CAM-ICU</keyword>
  <keyword>VNR</keyword>
  <keyword>BPS</keyword>
  <keyword>Propofol</keyword>
  <keyword>Midazolam</keyword>
  <keyword>Hydroxyzine</keyword>
  <keyword>Lorazepam</keyword>
  <keyword>Melatonin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Lorazepam</mesh_term>
    <mesh_term>Melatonin</mesh_term>
    <mesh_term>Hydroxyzine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

